---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002846"
form_type: "8-K"
ticker: "NTRA"
cik: "0001604821"
company_name: "Natera, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:22:27.119425+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Natera FY2024 preliminary revenue ~$1.7B (+56% YoY), positive cash inflow $86.3M

## Summary
- Q4 2024 revenue ~$472M (+52% YoY); FY2024 revenue ~$1.7B (+56% YoY), ~$53M above top end of guidance.
- Positive non-GAAP cash inflow of $86.3M in FY2024 vs. outflow of $267.1M in FY2023.
- Total tests processed in FY2024 ~3.06M (+22.8% YoY); Q4 oncology tests up 54.7% to ~150,800.
- Clinical oncology tests in FY2024 ~498,300 (+63% YoY); Q4 sequential increase of ~14,800 tests.
- Company to present additional updates at J.P. Morgan Healthcare Conference on Jan 15, 2025.

## SEC filing metadata
- accession: 0001104659-25-002846
- form_type: 8-K
- ticker: NTRA
- cik: 0001604821
- company_name: Natera, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604821/000110465925002846/0001104659-25-002846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604821/000110465925002846/tm253044d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002846
- JSON: https://secwatch.observer/filing/0001104659-25-002846.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002846.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.